Attia separates acute from chronic inflammation, works through which inflammatory markers are actually worth measuring versus which are noise, and what genuinely lowers chronic inflammatory burden. A practical counterpart to the mechanistic literature.
Listen →Dr. Adam Sewell, MD breaks down inflammaging — the persistent, low-grade inflammation that accelerates degeneration across the body's systems — and what actually moves the needle on it.
Listen →Andrew Huberman talks with mitochondria researcher Dr. Jared Rutter (University of Utah, HHMI) about how mitochondria generate cellular energy, regulate cell growth and division, and link to aging and cancer. The conversation frames metabolism as an emergent property of trillions of individual mitochondria-containing cells.
Listen →In mice, opioids and methamphetamine (but not natural rewards) trigger calcium influx through the mitochondrial calcium uniporter in dopamine-releasing nerve terminals, fueling the rapid ATP production that sustains drug-driven dopamine surges. Blocking this mitochondrial calcium channel genetically or pharmacologically reduced drug-induced dopamine release and addictive behavior without disrupting normal reward processing, pointing to it as a possible addiction drug target.
Read source →An investigation into the science — and the gaps in the science — behind BPC-157 and MOTS-c, including a look at the risks people rarely ask about.
Listen →A new nanobody-based delivery system precisely targets healthy donor mitochondria to damaged neurons, cardiac cells, and other specific cell types — rescuing degenerating neurons in both a human optic-nerve-atrophy cell model and mice. Still preclinical, but a concrete step toward treating primary mitochondrial diseases like TK2 deficiency.
Read source →In 535 adults with overweight or obesity from the DiOGenes cohort, researchers split insulin resistance into its muscle and liver forms and profiled 1,128 plasma proteins. Muscle insulin resistance tracked 160 proteins dominated by inflammatory pathways, including IL-6 signalling; liver insulin resistance tracked 81 proteins centred on the complement system, with lower IGFBP-1, IGFBP-2, adiponectin and SHBG. Only 12 proteins overlapped. The authors argue this supports tissue-specific rather than one-size-fits-all interventions.
Read source →Dr. Martin Picard (Columbia) explains how mitochondria translate behavior, psychology, and mindset into cellular energy production, and how exercise, nutrition, sleep, and stress reduction measurably affect mitochondrial function and aging markers.
Listen →Dr. Martin Picard (Columbia) explains how mitochondria translate behavior, psychology, and mindset into cellular energy production, and how exercise, nutrition, sleep, and stress reduction measurably affect mitochondrial function and aging markers.
Listen →Three geroscientists (rheumatology, neurology, and critical care) map how chronic low-grade inflammation shows up across specialties — from rheumatologic disease to traumatic brain injury — and where the gap is between wellness-marketing claims and actual evidence on inflammaging tests and treatments.
Listen →In a placebo-controlled RCT of 50 healthy middle-aged adults, 1,000 mg/day of urolithin A for 4 weeks expanded naive, less-exhausted CD8+ T cells and measurably increased mitochondrial biogenesis within those immune cells — a rare case of a supplement showing a measurable immune-aging effect this quickly. Conducted with the Buck Institute for Research on Aging.
Read source →The cardiolipin-targeting peptide SS-31/elamipretide became the first approved therapy for Barth syndrome, based on >45% improvement in knee extensor muscle strength in the Phase 2 TAZPOWER trial — a landmark for the whole mitochondrial-peptide class.
Read source →Eric Verdin, CEO of the Buck Institute for Research on Aging, on how immune aging — thymic shrinkage, narrowing T-cell diversity, weaker vaccine response — acts as a rate-limiting step in aging, and how chronic inflammation is both a consequence and an accelerant of it. Also covers NAD decline and CD38, the real limits of NMN/NR/IV NAD, rapamycin, and what aging clocks can and can't tell you.
Listen →A three-hour deep dive with metabolic researcher Ben Bikman on what actually drives insulin resistance, why insulin matters as a measure independently of glucose, how diet, exercise and sleep each move the needle, and where GLP-1 agonists fit into the picture. Hosted by Rhonda Patrick.
Listen →A three-hour deep dive with metabolic researcher Ben Bikman on what actually drives insulin resistance, why insulin matters as a measure independently of glucose, how diet, exercise and sleep each move the needle, and where GLP-1 agonists fit into the picture. Hosted by Rhonda Patrick.
Listen →The inflammaging signature derived from an Italian cohort (InCHIANTI) replicated in another industrialized population (Singapore), but largely vanished in two non-industrialized groups — the Tsimane of the Bolivian Amazon and the Orang Asli of Peninsular Malaysia. In those groups inflammation tracked infection burden rather than age, and showed little association with age-related disease. Suggests inflammaging may be substantially a byproduct of industrialized environments rather than a fixed feature of human aging.
Read source →Pools 13 systematic reviews (11 with meta-analyses) covering resistance, aerobic, combined, HIIT, tai chi, yoga and multimodal training in older adults. Exercise reliably lowered CRP across every review, with resistance training performing best, and reduced TNF-α in most reviews, with HIIT showing particular promise. IL-6 results were inconsistent, with combined aerobic-plus-resistance training doing best, and there was too little data to judge IL-10.
Read source →Ralph DeFronzo, M.D. — the researcher who helped bring metformin to the US and developed SGLT2 inhibitors — walks through the pathophysiology of insulin resistance across muscle, liver, and fat, and how it's measured, prevented, diagnosed, and treated.
Listen →Ralph DeFronzo, M.D. walks through the pathophysiology of insulin resistance across muscle, liver, and fat, and how it's measured, prevented, diagnosed, and treated.
Listen →Huberman and Attia dig into the NAD+ pathway, comparing NAD, NMN, and NR supplementation, routes of administration, and what the clinical literature actually supports for longevity.
Listen →López-Otín, Blasco, Partridge, Serrano & Kroemer expand the hallmarks of aging from 9 to 12, including mitochondrial dysfunction — and map how each hallmark reinforces the others.
Read source →A 4-month, placebo-controlled RCT (NCT03464500) found ~12% gains in muscle strength and improved mitochondrial biomarkers (lower plasma acylcarnitines and CRP) from the mitophagy-activating postbiotic Urolithin A.
Read source →Attia and Huberman work through the research on metformin as a longevity drug. Along the way Attia explains how insulin resistance develops — starting in muscle — and its role in type 2 diabetes. A useful look at how to read the evidence behind a much-hyped intervention.
Listen →This PRISMA systematic review pooled 113 studies (33 human, 80 rodent) on NAD+-boosting compounds like NR and NMN. It found rodent studies often showed metabolic and mitochondrial benefits, but in humans, oral NR/NMN reliably raised NAD+-related biomarkers while effects on real functional and health outcomes were mixed or null, and no outcomes trials existed yet for IV/wellness-clinic NAD+ infusions.
Read source →In transgenic mouse models, the mitochondrial-derived peptide MOTS-c boosted intrinsic muscle mitochondrial bioenergetics and lowered ROS-related oxidative damage — requiring both PGC-1α and AMPK signalling, without increasing raw mitochondrial volume. Animal data only; a human Phase 2a trial (MOTS-MET) for prediabetes began enrolling in 2026.
Read source →Using bioinformatic and protein-docking analysis, researchers compared the mitochondrial-derived peptide humanin across mammals with different oxidative-stress profiles (deep-diving cetaceans, high-metabolism shrews, long-lived primates). Species under greater oxidative stress carried more structurally stable humanin variants, suggesting evolution has tuned the peptide's protective function and offering a template for designing humanin-based therapeutic analogs.
Read source →A widely-read explainer on how glucose tolerance and mitochondrial energy output decline with age, and the practical levers (diet, exercise, sleep) with the most human evidence behind them for preserving metabolic health.
Read source →A 2026 Nature Metabolism review of how mitophagy, biogenesis, and mitochondrial network dynamics change with age, and what that means for healthspan interventions targeting mitochondrial quality rather than just quantity.
Read source →An evergreen research hub tracking the evidence base for Urolithin A as a mitophagy-inducing postbiotic, updated as new studies land.
Read source →Bikman's short-format lecture series on the practical side: which tests actually surface insulin resistance (and why fasting glucose alone routinely misses it), plus what changes it. Tighter and more focused than the long-form interviews.
Listen →Mitrix Bio is manufacturing donor mitochondria in bioreactors and infusing them into paying patients at Right to Try clinics in Texas, California, and Florida — including a 91-year-old physicist as one of its first two patients. No peer-reviewed efficacy data exists yet. Included as a development worth watching, not a recommendation — this is an unregulated, direct-to-consumer offering with an N of 2.
Read source →This narrative review synthesizes mechanistic and preclinical evidence that the supplement PQQ activates mitochondrial biogenesis pathways (CREB, PGC-1a, TFAM) and protects against oxidative injury, applying that evidence to skin aging and recovery after aesthetic procedures. The authors note the dermatology-specific human evidence base is still thin relative to the preclinical mechanism data.
Read source →Reviews dietary approaches to insulin resistance. The Mediterranean diet has the strongest evidence, with consistent HOMA-IR reductions and a 31% lower type 2 diabetes incidence in PREDIMED-Plus. Low-carbohydrate and ketogenic diets produce the largest short-term drops in fasting glucose and insulin, but their sustainability is unclear. The authors caution that most studies use surrogate indices, last 26 weeks or less, and struggle to separate diet effects from weight loss.
Read source →The design paper for a randomized, double-blind, placebo-controlled trial testing whether clazakizumab, an antibody that blocks interleukin-6, can improve or slow decline in physical, cognitive and vascular function in adults aged 70 and over with low-to-moderate physical function. It is a direct test of the geroscience idea that targeting inflammation itself can extend healthspan. No results yet — this paper describes the rationale and protocol.
Read source →A condensed Huberman Lab episode with Rhonda Patrick on four micronutrients that influence cellular stress responses, inflammation, detoxification and longevity, and why common shortfalls in them may matter more than people assume.
Listen →NYT's David Dodge and McGill's Jonathan Jarry unpack why injectable peptide therapy caught fire in the wellness world despite thin safety data.
Listen →This narrative review examines how heat acclimation protocols alter mitochondrial biogenesis and bioenergetic function across cell, rodent, and human studies, and links those subcellular changes to exercise performance gains. The authors propose a heat-acclimation protocol designed to maximize mitochondrial adaptation and flag open questions for future research.
Read source →Preclinical work showing MOTS-c, an mtDNA-encoded peptide, restores mitochondrial respiration and energy homeostasis in a type 2 diabetic cardiac model — building the mechanistic case for its "exercise mimetic" reputation.
Read source →Maps how age-associated chronic inflammation interacts with the other eleven hallmarks of aging, arguing the crosstalk forms a self-reinforcing cycle that accelerates cellular decline. A good orientation piece for why inflammation sits near the centre of the aging network rather than off to one side.
Read source →A deep dive into Zone 2 training dose, frequency, and duration, and how it drives mitochondrial biogenesis and oxidative capacity.
Listen →A masterclass on energy system pathways, fuel sources, exercise training zones, and mitochondrial function as both a diagnostic and treatment target for metabolic health.
Listen →